242 related articles for article (PubMed ID: 37591216)
1. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
3. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
4. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
8. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
12. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
Cai W; Tong R; Sun Y; Yao Y; Zhang J
Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
20. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
